* Neurosense Therapeutics Ltd NRSN.OQ NRSN.O is expected
to report resultson August 14 (estimated) for the period ending
June 30 2024
*
* LSEG's mean analyst estimate for Neurosense Therapeutics
Ltd is
for a loss of 20 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 7.9%
in the last three months.
* Wall Street's median 12-month price target for Neurosense
Therapeutics Ltd is $5.25, above its last closing price
of $0.66.
This summary was machine generated August 12 at 11:24 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)